Literature DB >> 26722418

Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma.

He Li1, Heping Xiang1, Weiwei Ge1, Hengtong Wang1, Tianpeng Wang1, Maoming Xiong2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors, with its 5-year survival rate lower than 5%. MicroRNAs (miR) have been known as important regulators for the tumorigenesis, progression, invasion and metastasis of various cancers. MiR-184 was found to be abnormally expressed in various cancers including glioma and oral carcinoma. The expression and functional role of miR-184 in PDAC, however, remains unclear. PDAC cell line PANC-1 was transfected with miR-184 inhibitor. Real-time PCR was used to detect the expression of miR-184 in untreated PANC-1, miR-184 inhibitor transfected PANC-1 and controlled normal pancreatic ductal epithelial cell line HPDE6c7. MTT assay was used to detect the effect of miR-184 on the proliferation of PANC-1 cells, while invasion assay and Western blotting were employed to describe the effect on cell invasion ability and expression of caspase-3, respectively. In PANC-1 cells, miR-184 was abundantly expressed. The transfection of inhibitor effectively suppressed the expression of miR-184, and further inhibited both cell proliferation and invasion abilities, in addition to the up-regulation of pro-apoptotic protein caspase 3 expression. The up-regulation of miR-184 in PDAC may facilitate the proliferation and invasion ability, and inhibit apoptosis of tumor cells, thus potentiating the occurrence and development of PDAC. MiR-184, therefore, is a potential molecular target for therapy.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma; micro RNA inhibitor; tumor proliferation and metastasis

Mesh:

Substances:

Year:  2015        PMID: 26722418      PMCID: PMC4680363     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

Review 1.  Recent advances in pancreatic cancer: biology, treatment, and prevention.

Authors:  Divya Singh; Ghanshyam Upadhyay; Rakesh K Srivastava; Sharmila Shankar
Journal:  Biochim Biophys Acta       Date:  2015-05-11

2.  MicroRNA-184 promotes proliferation ability of glioma cells by regulating FOXO3.

Authors:  Qing-Ke Cui; Wei-Dong Liu; Jian-Xin Zhu; Yun-Hua Wang; Zhi-Gang Wang
Journal:  Asian Pac J Trop Med       Date:  2014-10       Impact factor: 1.226

Review 3.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

Review 4.  Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers.

Authors:  Kirsten Lindner; Joerg Haier; Zhe Wang; David I Watson; Damian J Hussey; Richard Hummel
Journal:  Clin Sci (Lond)       Date:  2015-01       Impact factor: 6.124

Review 5.  MicroRNAs in colorectal cancer: from diagnosis to targeted therapy.

Authors:  Ayla Valinezhad Orang; Abolfazl Barzegari
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.

Authors:  J A Galván; I Zlobec; M Wartenberg; A Lugli; B Gloor; A Perren; E Karamitopoulou
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

7.  A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.

Authors:  Alakesh Bera; Kolaparthi VenkataSubbaRao; Muthu Saravanan Manoharan; Ping Hill; James W Freeman
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

8.  Single-Nucleotide Polymorphisms Within MicroRNAs Sequences and Their 3' UTR Target Sites May Regulate Gene Expression in Gastrointestinal Tract Cancers.

Authors:  Zahra Saadatian; Andrea Masotti; Ziba Nariman Saleh Fam; Behnam Alipoor; Milad Bastami; Hamid Ghaedi
Journal:  Iran Red Crescent Med J       Date:  2014-07-05       Impact factor: 0.611

9.  Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy.

Authors:  Hironobu Takano; Takahiro Tsuchikawa; Toru Nakamura; Keisuke Okamura; Toshiaki Shichinohe; Satoshi Hirano
Journal:  World J Surg Oncol       Date:  2015-06-26       Impact factor: 2.754

10.  Mature miR-184 and squamous cell carcinoma of the tongue.

Authors:  Thian-Sze Wong; Wai-Kuen Ho; Jimmy Yu-Wai Chan; Raymond Wai-Man Ng; William Ignace Wei
Journal:  ScientificWorldJournal       Date:  2009-02-15
View more
  5 in total

1.  Exposure to an environmentally relevant phthalate mixture during prostate development induces microRNA upregulation and transcriptome modulation in rats.

Authors:  Wellerson R Scarano; Amina Bedrat; Luiz G Alonso-Costa; Ariana M Aquino; Bruno Fantinatti; Luis A Justulin; Luis F Barbisan; Paula P Freire; Jodi A Flaws; Lemos Bernardo
Journal:  Toxicol Sci       Date:  2019-06-14       Impact factor: 4.849

2.  Effect of miR-184 and miR-205 on the tumorigenesis of conjunctival mucosa associated lymphoid tissue lymphoma through regulating RasL10B and TNFAIP8.

Authors:  Yu-Zhen Li; Pei Mou; Ya Shen; Lian-Di Gao; Xin-Xin Chen; Rui-Li Wei
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

3.  Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway.

Authors:  Zhenguang Du; Fusheng Li; Liangliang Wang; Hai Huang; Shaonian Xu
Journal:  Mol Med Rep       Date:  2018-06-18       Impact factor: 2.952

4.  [ARTICLE WITHDRAWN] Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184.

Authors: 
Journal:  Oncol Res       Date:  2017-06-22       Impact factor: 5.574

5.  Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.

Authors:  Yi-Fan Xu; Bethany N Hannafon; Yan D Zhao; Russell G Postier; Wei-Qun Ding
Journal:  Oncotarget       Date:  2017-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.